Details of the Drug

General Information of Drug (ID: DMLW9HG)

Drug Name
Tildrakizumab
Synonyms UNII-DEW6X41BEK; DEW6X41BEK; Tildrakizumab [USAN:INN]; SCH 900222
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Approved [1]
ATC Code
L04AC17: Tildrakizumab
L04AC: Interleukin inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Antibody
Sequence
>heavy chain
QVQLVQSGAEVKKPGASVKVSCKASGYIFITYWMTWVRQAPGQGLEWMGQIFPASGSADY
NEKFEGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARGGGGFAYWGQGTLVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
DIQMTQSPSSLSASVGDRVTITCRTSENIYSYLAWYQQKPGKAPKLLIYNAKTLAEGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQHHYGIPFTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 407 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 70 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2.25 h [2]
Bioavailability
The bioavailability of drug is 12% [2]
Clearance
The sytemic clearance of drug is 0.32 L/day [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 23 days [3]
Metabolism
The drug is metabolized via the catabolic pathways in a manner similar to endogenous IgG [3]
Vd
The volume of distribution (Vd) of drug is 10.8 L [3]
Cross-matching ID
UNII
DEW6X41BEK
DrugBank ID
DB14004
TTD ID
D0FT3R

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Modulator [1]
Interleukin-37 (IL37) TTQTX98 IL37_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-23 (IL23) DTT IL23A 5.37E-01 -0.1 -0.42
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 FDA Approved Drug Products: Orgovyx (relugolix) tablets for oral use
3 FDA Approves ILUMYA (tildrakizumab-asmn) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)